Suda Pharmaceuticals Ltd Ret. on assets
What is the Ret. on assets of Suda Pharmaceuticals Ltd?
The Ret. on assets of Suda Pharmaceuticals Ltd is -189.26%
What is the definition of Ret. on assets?
Return on assets indicates how profitable a company’s assets are in generating revenue. It is computed by dividing net income by average total assets.
ttm (trailing twelve months)
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Ret. on assets of companies in the Health Care sector on ASX compared to Suda Pharmaceuticals Ltd
What does Suda Pharmaceuticals Ltd do?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Companies with ret. on assets similar to Suda Pharmaceuticals Ltd
- Delta Resources has Ret. on assets of -192.39%
- Adynxx has Ret. on assets of -192.35%
- Urovant Sciences Ltd has Ret. on assets of -191.60%
- Esports Entertainment has Ret. on assets of -191.47%
- Medcolcanna Organics has Ret. on assets of -189.86%
- Cloud DX has Ret. on assets of -189.85%
- Suda Pharmaceuticals Ltd has Ret. on assets of -189.26%
- IncentiaPay has Ret. on assets of -189.11%
- Portex Minerals has Ret. on assets of -188.92%
- KULR Technology has Ret. on assets of -187.61%
- Crown ElectroKinetics has Ret. on assets of -187.30%
- Loop Insights has Ret. on assets of -187.23%
- Fobi Ai has Ret. on assets of -187.23%